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Background: Japan started using the CARELINK (Medtronic, Inc, Minneapolis, MN,
USA) remote monitoring system in April 2009. However, in some cases, the device failed
to transmit a message after registration or according to schedule. We investigated the
diﬀerence between patients who could make eﬀective use of CARELINK system and those
who could not.
Subjects and Method: Sixty patients who had registered until December 2009 at our
institution were analyzed. These patients were divided into two groups: those who were able
to use the device eﬀectively (group G, n ¼ 49) and those who were not (group F ¼ 11).
Patient background, automatic or manual telemetries, new or existing implant patient,
presence of adverse events, and the use or non-use of a checklist at the time of introduction
were compared between the two groups.
Results: In group G, more patients used a checklist at the time of introduction than that
in group F (use of checklist/total, 31/49 in group G vs. 3/11 in group F; P, 0.029). No
signiﬁcant diﬀerence was observed in other factors between the two groups.
Conclusion: We consider that the method used to explain the system are important to make
the patients understand handling methods of CARELINK system. The number of patients
introduced to remote monitoring of implantable devices will continue to increase in the
future; therefore, we must continue to develop innovative approaches for their eﬀective use.
(J Arrhythmia 2011; 27: 126–130)
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Introduction
Pacemakers (PM) and implantable cardioverter
deﬁbrillators (ICD) have been used to treat patients
with symptomatic bradycardia and those at risk
for sudden death due to ventricular arrhythmia.1)
Furthermore, cardiac resynchronization therapy
with a deﬁbrillation function (CRT-D) has become
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more popular for treating patients with systolic
dysfunction and left ventricular dyssynchrony; thus,
the number of patients with implants has increas-
ed.2–4)
Patients with implanted devices must have
the condition of the devices checked and receive
medical examination from a physician on a regular
basis, although the frequency of follow-up checkups
varies depending on the implant type and disease.
Patients implanted with ICD as primary prevention
for cardiac arrhythmia events do not always feel
motivated to visit the ICD clinic regularly.5–9) In
addition, in some cases of asymptomatic cardiac
arrhythmia, the arrhythmia events were not detected
until the next outpatient visit. However, a quick
intervention is possible if we can identify these
events using remote monitoring.
To solve these problems, a remote monitoring
system (CARELINK; Medtronic, Inc., Minneapolis,
MN, USA) has become available. Through this
system patients can view accumulated data on a
dedicated web site using a telephone line at home,
and obtain information similar to that obtained from
a device checkup conducted at an outpatient visit.4)
An improvement in patient care has been recognized
in various clinical studies conducted on this remote
monitoring system.10–13)
Japan lags behind Europe and the US in the use
of this remote monitoring system. In our institution,
we introduce the CARELINK system to patients
soon after they are admitted. However, some patients
could not use this system eﬀectively, i.e., the device
failed to transmit a message after registration or
according to schedule. To take advantage of the
CARELINK remote monitoring system, we inves-
tigated the diﬀerence between patients who could
make eﬀective use of the CARELINK system and
those who could not.
Methods
Sixty patients who completed registration between
April 2009 and December 2009 were included in
the study. Eleven patients were implanted with PM
(7 Adapta, 4 EnRhythm); 44 with ICD (21 Maximo,
15 Virtuoso, 8 Secura); and 5 with CRT-D (5
Concerto). All devices used were manufactured by
Medtronic, Inc. Patients were divided into two
groups: those who could use the device eﬀectively
(group G) and those who could not (group F).
Group G comprised 49 patients and group F com-
prised 11 patients. We compared patient background,
gender ratio, age, device type, and diﬀerences in
interrogation between the two groups.
All PM models required manual data reading and
transmission by the patient each time. Of the ICD,
only the Maximo required manual data reading and
transmission. The remaining devices were automatic
such that they required manual data reading and
transmission by the patient during its ﬁrst use, and
after the second use, the device automatically read
and transmitted the data via an antenna incorporated
in the device.
After regular checkup at a periodic outpatient
visit and when the existing implant device was
deemed compatible with the CARELINK system,
the patient received an explanation about the
CARELINK system from the physician during a
consultation. The patient returned to the room where
the device checkup was conducted and received an
explanation about installation and handling of the
device from the clinical engineering technologist.
The patient then returned to the consultation room
and obtained the physician’s signature on a written
consent to complete the procedure.
In our institution when a patient receives an
implantation for the ﬁrst time, a checkup is con-
ducted a week after implantation. Such a patient
receives an explanation about the CARELINK
system at the ﬁrst checkup and obtains the phys-
ician’s signature on a written consent. For new
implants, the patient does not have to travel between
rooms, unlike those with existing implants.
The presence of atrial or ventricular arrhythmia
events was recorded and a checklist was presented to
the patient during the explanation (Figure 1).
The checklist for the explanation details provided
to the patients was not used during the period
from April 2009 until July 2009, and was used
during the period from August 2009 until December
2009.
Statistical Analysis
The unpaired t-test and 2 2 chi-square test were
used. P < 0:05 was considered statistically signiﬁ-
cant.
Results
No signiﬁcant diﬀerence was observed in patient
background or devices used between the two groups.
Furthermore, no signiﬁcant diﬀerence was observed
for other examination factors, i.e., diﬀerence in
interrogation, diﬀerence upon introduction of the
CARELINK system, and presence of atrial ar-
rhythmias. In group G, the percentage of patients
who were using the checklist at the time of
introduction was signiﬁcantly higher than that in
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group F (use of checklist/total = 31/49 in group G
vs. 3/11 in group F, P ¼ 0:029) (Table 1).
The problems faced by the 11 patients who could
not use the device eﬀectively were as follows:
the device failed to transmit the ﬁrst message
(5 cases); failed to transmit messages according
to the schedule (4 cases); delay in transmission
(1 case); and mechanical problem (1 case).
Discussion
The number of patients with PM, ICD, and CRTD,
and those attending PM clinics is annually increas-
ing. Patients implanted with ICD as primary pre-
vention for cardiac arrhythmia events do not always
feel motivated to visit the ICD clinic regularly.5–9) In
addition, in some cases with asymptomatic cardiac
Confirmation of a necessary part
Check factor Contents
Necessary part / 
name of each part Explanation of a button switchExplanation of a lamp
•Main body (an antenna) / telephone cord / power adaptor
•A start•stop button / a line changeover switch
•Power supply ON • Off/a lamp during the transmission and reading
About environment / 
the establishment*
Confirmation of using a telephone
Confirmation of the presence of a telephone
Confirmation of connection methods 
Confirmation of a phone line
•Black telephone NG (IP**/ light : OK)
•Is an establishment place living environment 3 m range; (a bedroom best) 
•Only telephone connection/Confirmation of internet line connection
•tone (T),  pulse (P) line :In the case of a light line a tone (T)
There are many cases of a tone (T)
Data reading / 
transmission
Confirmation of a power supply
Data reading
A downlink
•A lamp turns on***
•The reading that is worked by hand/Automatic reading****
(the first time) (completed in around 2 minutes)
•Transmission methods and transmission completion
(Even if an antenna is separated, during the transmission, there is not no 
problem. Afterwards, transmission completion is confirmed)
About an alert
Confirmation of an alert sound
Setting of an alert
•Convey that alarm sounds from machinery*****
Have you heard the sound at Demo (High or Low)
•Make setting of Clinical Management Alerts / Lead/Device Integrity Alerts On
Troubleshooting
A transmission error
At the time of staying out
•Change setting of a phone line (T/P)•Confirmation of connection
•When we are away from home for a long term, a setting change is 
necessary(care alert Off)
Matters that require attention
Figure 1 Checklist
A pamphlet was used to explain the contents of the checklist to each patient. The contents of the checklist was describe to the patient. After
the checklist was described, the following items were explained.
The device is operational as soon as it arrives and the ﬁrst time it transmits a message.
An IP telephone may be used.
The device is automatically set the ﬁrst time it is used after it has been oﬀ-line.
The light indicates that the power is on.
In the manual mode, the data is transmitted before coming to the hospital
Contact the hospital when an alarm sounds.
Table 1 Comparison of group G and group F for each factor
Group G Group F P value
Sex ratio
(male : female) 38 : 11 10 : 1 0.316
Age
(means SD) 58 15 50 22 0.112
Device type
(PM : ICD/CRT-D) 9 : 40 2 : 9 0.988
Difference in Interrogation
(Manual type : Automatic type) 25 : 24 8 : 3 0.190
Difference Upon Introduction of
CARELINK (outpatient : inpatient) 33 : 16 8 : 3 0.728
Presence of Events
(existence : nothing) 14 : 35 5 : 6 0.276
Use of Checklist upon Explanation
(use : mint condition) 31 : 18 3 : 8 0.029
P value is shown comparing the patient who could utilize the CARELINK system versus those who could not. Unpaired t-test
was used for the statistical analysis. P < 0:05 is considered signiﬁcant.
Implanted devices in the case of a CARELINK supported model
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arrhythmia, arrhythmia events were not detected
until the next outpatient visit. If these events are
detected immediately, we can intervene as soon as
possible. To solve these problems, the CARELINK
remote monitoring system is now available. How-
ever, Japan lags behind Europe and the US in the use
of this remote monitoring system. In our institution,
we introduced the CARELINK system soon after
patient admission. However, some patients could not
use this system eﬀectively, i.e., the device failed to
transmit a message after registration or according to
schedule. To take advantage of the CARELINK
remote monitoring system we investigated the
possible causes of such problems in patients who
could use the device eﬀectively and those who
could not. As a result, using a checklist when the
CARELINK system is introduced is important to
ensure its eﬀective utilization.
We created a checklist and began using it as a tool
for staﬀ members to standardize the explanation
procedure during CARELINK introduction. Ac-
cording to some reports, the use of a checklist is
eﬀective not only for those explaining the system
but also for the patients who receive the explanation.
We cannot exclude the possibility from repeating
an explanation or staﬀ explanation methods improv-
ing, but introducing the CARELINK system was
valuable, hence, we can exclude habituation eﬀects.
The reason patients could not perform the trans-
mission for the ﬁrst time after the device was
introduced was because they forgot the data uptake
method. A checklist may make the use of the
CARELINK system more easily understandable.
The patient in whom transmission of a message
failed according to schedule forgot to switch the
instrument on. We believe that this error would
decrease with the use of a checklist as it indicates
that a green light comes on when the device is
operational. In cases of instrument problems, the
patients were unable to use a phone line because
their phones were on IP lines.
The patient must manually perform data reading
and transmission at the ﬁrst transmission, which is
a burden. However, operation is simple and easy,
and no signiﬁcant diﬀerence was observed in trans-
mission methods as previously reported.14)
Furthermore, no diﬀerence was observed in the
interrogation methods. For the manual type of
device, all patients were required to manually
perform data reading and transmission each time.
With the automatic type, patients were required to
manually perform data reading and transmission at
the ﬁrst use, and transmission was automatic via
an antenna incorporated in the device from the
second use. No diﬀerence was presented between
the manual and automatic types because they used
the manual transmission of data at the ﬁrst use, and
the method was easy.
Furthermore, no diﬀerences were observed be-
tween the time of introduction of the CARELINK
system at the inpatient versus the outpatient clinic.
This may be because patients faced the same
situation with little knowledge of the remote mon-
itoring system.
No signiﬁcant diﬀerence was observed in the
presence or absence of adverse events, possibly
because the patients failed to notice the occurrence
of adverse events in the absence of shock therapy.
Therefore, in the cases in which the manual
CARELINK type was used, the problem would
not be discovered until the next outpatient check-
up.15–22) However, in the future, an automatic type of
the remote monitoring system will be widely used,
and hence, the system will be more eﬀective.
Conclusion
The patients using the CARELINK system had
to set up telecommunication equipment at the time of
ﬁrst use and communicate via the equipment by
themselves. Therefore, we consider that the methods
of explanation are important to make the patients
understand how to handle the CARELINK system
correctly. The number of patients introduced to
remote monitoring of implantable devices will
continue to increase in the future; therefore, we
must develop innovative approaches for their eﬀec-
tive use.
Study Limitations
We retrospectively investigated possible causes
of problems in patients who could not eﬀectively
use the CARELINK monitoring system. The use
of a checklist at the time of device introduction
was suggested as a factor for the eﬀective use of
the CARELINK system.
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